Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial
Official title:
Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the
laboratory may help doctors learn more about T cells and plan better treatment for multiple
myeloma.
PURPOSE: This research study is looking at T cells in blood and bone marrow samples from
patients with multiple myeloma.
OBJECTIVES:
Primary
- To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex
vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs)
in peripheral blood and bone marrow samples from patients with multiple myeloma.
Secondary
- To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo
using interferon γ release and CD3/CD28 stimulation.
OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory
studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex
vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell
antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function
of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting
T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T
cells are expanded ex vivo using anti CD3/CD28 beads.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00568880 -
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Recruiting |
NCT01137825 -
Registry of Older Patients With Cancer
|
||
| Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
| Completed |
NCT00313625 -
Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma
|
Phase 2 | |
| Terminated |
NCT00608517 -
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
|
N/A | |
| Completed |
NCT00898066 -
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
|
N/A | |
| Completed |
NCT00478075 -
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT00951626 -
A Standardized Nursing Intervention Protocol for HCT Patients
|
N/A | |
| Completed |
NCT00301951 -
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
|
Phase 1 | |
| Terminated |
NCT00369291 -
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT00937183 -
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
|
N/A | |
| Completed |
NCT00049374 -
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT00004072 -
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT00003399 -
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT00003396 -
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Completed |
NCT00003398 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 4 | |
| Active, not recruiting |
NCT00003163 -
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
|
Phase 2 | |
| Terminated |
NCT00005641 -
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT00002599 -
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
|
Phase 3 |